Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 10,816 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Developmental Defect Clear all
Completed No phase listed Observational Accepts healthy volunteers

The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)

NCT00822276
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis, Eczema Herpeticum, MRSA
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
San Diego, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Oct 31, 2026, 3:52 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Development and Evaluation of an Information Management System and Communication System for Population-wide Point-of-care Infant Sickle Cell Disease Screening

NCT06563440
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Digital app and information system
Other
Lead sponsor
Makerere University
Other
Eligibility
Up to 5 Years
Enrollment
24,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 31, 2026, 3:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema

NCT02357940
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Experimental Product
Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
6 Months and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
St. Petersburg, Florida • Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 31, 2026, 3:52 PM EDT
Active, not recruiting Phase 4 Interventional

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

NCT04323189
View directory record Official record
Conditions
Genetics Disease, Type2 Diabetes, Heart Failure
Interventions
Sitagliptin 100mg, Placebo Oral Tablet
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 31, 2026, 3:52 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Behavioral Assessment and Treatment of Problem Behavior in Children With Cornelia de Lange Syndrome

NCT05829668
View directory record Official record
Conditions
Cornelia de Lange Syndrome
Interventions
ABA-based functional analysis and treatment
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
3 Years to 15 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 31, 2026, 3:52 PM EDT
Not listed No phase listed Observational

A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501

NCT04080050
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy
Drug
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
Columbus, Ohio • Portland, Oregon • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 31, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

NCT02141074
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia B
Interventions
nonacog beta pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
0 Years to 6 Years · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Gainesville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 31, 2026, 3:52 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy

NCT02310763
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
PF-06252616, Placebo
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 15 Years · Male only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 31, 2026, 3:52 PM EDT
Recruiting No phase listed Observational

Fetoscopic Neural Tube Defect Repair

NCT06946563
View directory record Official record
Conditions
Neural Tube Defects, Spina Bifida
Interventions
Fetoscopic Neural Tube Defect Repair Devices
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 31, 2026, 3:52 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

NCT02895906
View directory record Official record
Conditions
22q11.2 Deletion Syndrome
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 31, 2026, 3:52 PM EDT
Not yet recruiting Early Phase 1 Interventional

A Pilot Study to Examine the Efficacy and Tolerability of Sirolimus on Epidermal Nevi Lesions in Patients 6 Years Old and Above.

NCT07813533
View directory record Official record
Conditions
Epidermal Nevi
Interventions
sirolimus topical gel 0.2%
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 3:52 PM EDT
Terminated Phase 2 Interventional

Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00096148
View directory record Official record
Conditions
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
idarubicin, cytarabine, bevacizumab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 59 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 31, 2026, 3:52 PM EDT
Enrolling by invitation Phase 4 Interventional

Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE

NCT05492799
View directory record Official record
Conditions
MPS III B
Interventions
AX 250
Drug
Lead sponsor
Allievex Corporation
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Oakland, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 31, 2026, 3:52 PM EDT
Recruiting Not applicable Interventional

Safety and Efficacy of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Congenital Diaphragmatic Hernia (CDH)

NCT07577414
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia
Interventions
FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)
Device
Lead sponsor
Dr Erin Perrone
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 31, 2026, 3:52 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain

NCT01743625
View directory record Official record
Conditions
Pain, Postoperative, Bunion
Interventions
COV155, placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Anaheim, California • Pasadena, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 31, 2026, 3:52 PM EDT
Suspended Phase 2 Interventional

A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome

NCT01325740
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
STX107
Drug
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 31, 2026, 3:52 PM EDT
Completed Not applicable Interventional

Physical Activity in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

NCT00554489
View directory record Official record
Conditions
Leukemia
Interventions
exercise intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 31, 2026, 3:52 PM EDT
Completed Not applicable Interventional

Pompe Disease QMUS and EIM

NCT02742298
View directory record Official record
Conditions
Pompe Disease
Interventions
Muscle ultrasound, Electrical Impedance Myography
Device · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 31, 2026, 3:52 PM EDT
Recruiting No phase listed Observational

Rett Syndrome Registry

NCT05432349
View directory record Official record
Conditions
Rett Syndrome, Rett Syndrome, Atypical, Genetic Disease, Genetic Diseases, X-Linked, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Neurologic Disorder, Neurodevelopmental Disorders, Nervous System Diseases
Interventions
Not listed
Lead sponsor
International Rett Syndrome Foundation
Other
Eligibility
0 Years to 99 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 3:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores

NCT02779426
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Text messages
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
Up to 6 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 31, 2026, 3:52 PM EDT
Completed No phase listed Observational

Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis

NCT00379678
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 31, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

Dexamethasone Treatment of Congenital Adrenal Hyperplasia

NCT00621985
View directory record Official record
Conditions
Adrenal Hyperplasia, Congenital
Interventions
dexamethasone, Hydrocortisone
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 9 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 31, 2026, 3:52 PM EDT
Completed Not applicable Interventional

Fluid Restriction in Respiratory Distress of the Newborn

NCT03120585
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Fluid Management Intervention
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
Up to 12 Hours
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
New York, New York • Lawton, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 31, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients

NCT01975935
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
Interventions
Amlexanox, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 31, 2026, 3:52 PM EDT